Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 2:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 88 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Sponsor: Premier Research Clear all
Completed Phase 3 Interventional Results available

A Phase III Study of the Efficacy and Safety of Remimazolam Compared to Placebo and Midazolam in Colonoscopy Patients

NCT02290873
View directory record Official record
Conditions
Colonoscopy
Interventions
Remimazolam, Midazolam, Placebo
Drug
Lead sponsor
Paion UK Ltd.
Industry
Eligibility
18 Years and older
Enrollment
461 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
13
States / cities
Mobile, Alabama • Anaheim, California • Chula Vista, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Sep 24, 2026, 2:02 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of an Antibiotic Implant in Cardiac Surgical Subjects at Higher Risk for Sternal Wound Infection

NCT00600483
View directory record Official record
Conditions
Cardiac Surgery, Sternal Wound Infection
Interventions
gentamicin-collagen sponge dipped in saline
Drug
Lead sponsor
Innocoll
Industry
Eligibility
18 Years and older
Enrollment
1,502 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
43
States / cities
Birmingham, Alabama • Florence, Alabama • Pasadena, California + 39 more
Source: ClinicalTrials.gov public record
Updated May 4, 2022 · Synced Sep 24, 2026, 2:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of Serum Testosterone and Nestorone in Females After Secondary Exposure to Nestorone ® (NES) + Testosterone (T) Combined Gel Applied to Shoulders and Upper Arms in Males

NCT02994602
View directory record Official record
Conditions
Healthy Men, Male Contraception, Healthy Women, Product Transference
Interventions
Nestorone + Testosterone Combination Gel
Drug
Lead sponsor
Kimberly Myer
Other
Eligibility
18 Years to 50 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
2
States / cities
Torrance, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Sep 24, 2026, 2:02 AM EDT
Completed Phase 3 Interventional Results available

A Study (Study 2) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea

NCT04608500
View directory record Official record
Conditions
Facial Papulopustular Rosacea
Interventions
FMX103 minocycline foam 1.5%, Vehicle foam
Drug
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
771 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
46
States / cities
Glendale, Arizona • Hot Springs, Arkansas • Rogers, Arkansas + 39 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Sep 24, 2026, 2:02 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

28-Day Repeat-Dose, Dose Escalation Study of 11-β Methyl Nortestosterone Dodecylcarbonate (11β-MNTDC) in Healthy Men

NCT03298373
View directory record Official record
Conditions
Healthy Men, Male Contraception
Interventions
Placebo, 11β-methyl-nortestosterone-dodecylcarbonate
Drug
Lead sponsor
Premier Research
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
2
States / cities
Torrance, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 11, 2019 · Synced Sep 24, 2026, 2:02 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Study Comparing Emergency Contraception Effectiveness in Women Who Weight ≥ 80 kg

NCT03537768
View directory record Official record
Conditions
Contraception
Interventions
Ulipristal Acetate, Levonorgestrel
Drug
Lead sponsor
Kimberly Myer
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
532 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
18
States / cities
Los Angeles, California • Sacramento, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Sep 24, 2026, 2:02 AM EDT
Completed Phase 3 Interventional

Ibuprofen Liquid Capsules 2 x 200 mg Efficacy and PK/PD Study in Surgical Removal of Impacted Third Molars

NCT05484401
View directory record Official record
Conditions
Tooth, Impacted, Tooth Diseases, Stomatognathic Diseases
Interventions
Ibuprofen 200Mg Oral Cap, Ibuprofen 200Mg Oral Tablet, Placebo Liquid Capsule, Placebo Tablets
Drug · Other
Lead sponsor
Reckitt Benckiser Healthcare (UK) Limited
Industry
Eligibility
16 Years to 55 Years
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 24, 2026, 2:02 AM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetics, Relative Bioavailability and Safety of Xaracoll Implant

NCT02232178
View directory record Official record
Conditions
Hernioplasty
Interventions
2 100mg Xaracoll implants, 3 100mg Xaracoll implants, 150mg Bupivacaine HCl injection
Drug
Lead sponsor
Innocoll
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
5
States / cities
Anniston, Alabama • Sheffield, Alabama • Columbus, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Sep 24, 2026, 2:02 AM EDT
Terminated Phase 2 Interventional Results available

Study of Varespladib in Patients Hospitalized With Severe COVID-19

NCT04969991
View directory record Official record
Conditions
Coronavirus Disease 2019, Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2
Interventions
Varespladib, Placebo
Drug
Lead sponsor
Ophirex, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Ventura, California • Miami, Florida • Munster, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Sep 24, 2026, 2:02 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Amphetamine Extended-Release Tablets in the Treatment of Adults With ADHD

NCT03834766
View directory record Official record
Conditions
ADHD
Interventions
AMPH ER Tab 5, 10, 15 and 20 mg, AMPH ER Tab Matching Placebo 5, 10, 15 and 20 mg
Drug
Lead sponsor
Tris Pharma, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
3
States / cities
Bradenton, Florida • Maitland, Florida • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Sep 24, 2026, 2:02 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Dose-finding Study to Evaluate the Effect of a Contraceptive Vaginal Ring, Releasing Nestorone® and Estradiol, on Cycle Control, Ovulation Inhibition, and Pharmacokinetics in Normal Cycling Women

NCT01586000
View directory record Official record
Conditions
Suppression of Ovulation
Interventions
10 µg/day E2 with NES 200® µg/day, 20 µg/day E2 with NES 200® µg/day, 40 µg/day E2 with NES 200® µg/day
Drug
Lead sponsor
Kimberly Myer
Other
Eligibility
18 Years to 39 Years · Female only
Enrollment
197 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
8
States / cities
Baltimore, Maryland • New York, New York • Cincinnati, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2025 · Synced Sep 24, 2026, 2:02 AM EDT
Completed Phase 2 Interventional Results available

Multiple Dose Safety and Efficacy Study Evaluating CNS 7056 Versus Midazolam in Patients Undergoing Colonoscopy

NCT01145222
View directory record Official record
Conditions
Sedation
Interventions
A. CNS 7056, B. CNS 7056, C. CNS 7056, D. Midazolam
Drug
Lead sponsor
Paion UK Ltd.
Industry
Eligibility
18 Years to 70 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
9
States / cities
Sheffield, Alabama • Phoenix, Arizona • Anaheim, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Sep 24, 2026, 2:02 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Dose Finding Study of Contraceptive Vaginal Ring With Different Estradiol Levels in Combination With Nestorone

NCT02626208
View directory record Official record
Conditions
Suppression of Ovulation
Interventions
Nestorone®/Estradiol Contraceptive Vaginal Ring
Device
Lead sponsor
Premier Research
Other
Eligibility
18 Years to 39 Years · Female only
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
7
States / cities
Sacramento, California • New York, New York • Cincinnati, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2017 · Synced Sep 24, 2026, 2:02 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Efficacy Study of Two Continuous Regimens of Oral Daily 5 mg or 10 mg of Ulipristal Acetate (UPA), Versus a Dose of 5.0mg UPA for 24/4 Days

NCT01953679
View directory record Official record
Conditions
Focus: Estrogen-free Oral Contraception
Interventions
Ulipristal Acetate
Drug
Lead sponsor
Premier Research
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
10
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2016 · Synced Sep 24, 2026, 2:02 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Compare Two Copper IUDs: Mona Lisa NT Cu380 Mini and ParaGard

NCT03124160
View directory record Official record
Conditions
Healthy Women, Female Contraception
Interventions
Mona Lisa® NT Cu380 Mini, ParaGard® TCu380A
Drug
Lead sponsor
FHI 360
Other
Eligibility
16 Years to 40 Years · Female only
Enrollment
1,105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
16
States / cities
Los Angeles, California • Sacramento, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Sep 24, 2026, 2:02 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of RLS-0071 in Newborns With Moderate or Severe Hypoxic-Ischemic Encephalopathy Undergoing Therapeutic Hypothermia

NCT05778188
View directory record Official record
Conditions
Hypoxic-Ischemic Encephalopathy
Interventions
RLS-0071, Placebo
Drug
Lead sponsor
ReAlta Life Sciences, Inc.
Industry
Eligibility
Up to 10 Hours
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
15
States / cities
Little Rock, Arkansas • Orange, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 24, 2026, 2:02 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of NYX-783 in Subjects With Post-Traumatic Stress Disorder

NCT04044664
View directory record Official record
Conditions
Post-Traumatic Stress Disorder
Interventions
Placebo oral capsule, NYX-783
Drug
Lead sponsor
Aptinyx
Industry
Eligibility
18 Years to 65 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
37
States / cities
Tuscaloosa, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated May 16, 2022 · Synced Sep 24, 2026, 2:02 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating the Equivalence of GDC-229 and Metronidazole Vaginal Gel 0.75% in the Treatment of Bacterial Vaginosis

NCT03091777
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
GDC-229, Metronidazole Vaginal Gel 0.75%, Placebo
Drug
Lead sponsor
Balmoral Medical company
Industry
Eligibility
18 Years and older · Female only
Enrollment
871 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 6, 2020 · Synced Sep 24, 2026, 2:02 AM EDT
Completed Phase 3 Interventional Results available

The Efficacy Of Diclectin® For Nausea And Vomiting Of Pregnancy

NCT00614445
View directory record Official record
Conditions
Nausea and Vomiting of Pregnancy
Interventions
doxylamine succinate 10 mg/pyridoxine hydrochloride 10 mg, Placebo
Drug
Lead sponsor
Duchesnay Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland • Pittsburgh, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2021 · Synced Sep 24, 2026, 2:02 AM EDT
Terminated Phase 2 Interventional Results available

The Purpose of This Study is to Determine if Tetrodotoxin (TTX) is Effective in the Treatment of Pain Resulting From Chemotherapy Treatment

NCT01655823
View directory record Official record
Conditions
Pain, Peripheral Neuropathy, Neuropathic Pain
Interventions
Placebo, Tetrodotoxin
Drug
Lead sponsor
Wex Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
23
States / cities
Fountain Valley, California • Laguna Hills, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2018 · Synced Sep 24, 2026, 2:02 AM EDT
Completed Phase 3 Interventional Results available

A Phase III Study of Remimazolam in Patients Undergoing Bronchoscopy

NCT02296892
View directory record Official record
Conditions
Bronchoscopy
Interventions
Remimazolam, Placebo, Midazolam
Drug
Lead sponsor
Paion UK Ltd.
Industry
Eligibility
18 Years and older
Enrollment
446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
14
States / cities
Brandon, Florida • Sun City Center, Florida • Michigan City, Indiana + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Sep 24, 2026, 2:02 AM EDT
Completed Phase 2 Interventional

Alfimeprase for Thrombolysis in Acute Peripheral Arterial Occlusion

NCT00073554
View directory record Official record
Conditions
Arterial Occlusive Diseases, Peripheral Vascular Diseases, Thrombosis
Interventions
Alfimeprase
Drug
Lead sponsor
ARCA Biopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 16, 2009 · Synced Sep 24, 2026, 2:02 AM EDT
Completed Phase 2 Interventional Results available

The Safety and Efficacy of an Antibiotic Sponge in Diabetic Patients With Moderately Infected Foot Ulcers

NCT00659646
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
gentamicin-collagen sponge and levofloxacin, Levofloxacin only
Drug
Lead sponsor
Innocoll
Industry
Eligibility
18 Years to 80 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Lakeland, Florida
Source: ClinicalTrials.gov public record
Updated Jan 26, 2022 · Synced Sep 24, 2026, 2:02 AM EDT
Completed Phase 2 Interventional Results available

Effects of Ecopipam or Placebo in Adults With Stuttering (Speak Freely)

NCT04492956
View directory record Official record
Conditions
Childhood-Onset Fluency Disorder (Stuttering)
Interventions
Ecopipam, Placebo
Drug
Lead sponsor
Emalex Biosciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
9
States / cities
Riverside, California • Santa Ana, California • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Sep 24, 2026, 2:02 AM EDT